Reversing interleukin-2 inhibition mediated by anti-double-stranded DNA autoantibody ameliorates glomerulonephritis in MRL-lpr/lpr mice

Arthritis and Rheumatism

Volumn 62, Issue 8, 2010, Pages 2401-2411

  Song, Ying Chyi ^a   Tang, Shye Jye ^b   Lee, Tai Ping ^a   Hung, Wen Chien ^a   Lin, Shu Chi ^a   Tsai, Chang Youh ^c   Ng, Wailap Victor ^a   Wu, Ming Fang ^d   Sun, Kuang Hui ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ARGININE DERIVATIVE; DECA ARGININE; DOUBLE STRANDED DNA ANTIBODY; GLYCOGEN SYNTHASE KINASE 3; INTERLEUKIN 2; LITHIUM CHLORIDE; MONOCLONAL ANTIBODY 9D7; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; FEMALE; GLOMERULONEPHRITIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; LEUKEMIA CELL LINE; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; BLOTTING, WESTERN; CELL LINE; CELLS, CULTURED; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULONEPHRITIS; HUMANS; INTERLEUKIN-2; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED MRL LPR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 77955402786     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27487     Document Type: Article

References (42)

1. Berden JH. Lupus nephritis. Kidney Int 1997;52:538-58.
2. Tsao BP, Ohnishi K, Cheroutre H, Mitchell B, Teitell M, Mixter P, et al. Failed self-tolerance and autoimmunity in IgG anti-DNA transgenic mice. J Immunol 1992;149:350-8.
3. Lambert PH, Dixon FJ. Pathogenesis of the glomerulonephritis of NZB/W mice. J Exp Med 1968;127:507-22.
4. Gavalchin J, Datta SK. The NZB x SWR model of lupus nephritis. II. Autoantibodies deposited in renal lesions show a distinctive and restricted idiotypic diversity. J Immunol 1987;138:138-48. (Pubitemid 17218411)
5. Gauthier VJ, Mannik M. A small proportion of cationic antibodies in immune complexes is sufficient to mediate their deposition in glomeruli. J Immunol 1990;145:3348-52.
6. Tsao BP, Ebling FM, Roman C, Panosian-Sahakian N, Calame K, Hahn BH. Structural characteristics of the variable regions of immunoglobulin genes encoding a pathogenic autoantibody in murine lupus. J Clin Invest 1990;85:530-40. (Pubitemid 20070062)
7. Vlahakos DV, Foster MH, Adams S, Katz M, Ucci AA, Barrett KJ, et al. Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int 1992;41:1690-700.
8. Munoz LE, Gaipl US, Herrmann M. Predictive value of anti-dsDNA autoantibodies: importance of the assay. Autoimmun Rev 2008;7:594-7.
9. Yung S, Chan TM. Anti-DNA antibodies in the pathogenesis of lupus nephritis - the emerging mechanisms. Autoimmun Rev 2008;7:317-21.
10. Ruiz-Arguelles A, Rivadeneyra-Espinoza L, and Alarcon-Segovia D. Antibody penetration into living cells: pathogenic, preventive and immuno-therapeutic implications. Curr Pharm Des 2003;9:1881-7. (Pubitemid 37010091)
11. Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol 2004;172:3983-8.
12. Crabtree GR. Contingent genetic regulatory events in T lymphocyte activation. Science 1989;243:355-61.
13. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997;15:707-47. (Pubitemid 27169297)
14. Powell JD, Lerner CG, Ewoldt GR, Schwartz RH. The - 180 site of the IL-2 promoter is the target of CREB/CREM binding in T cell anergy. J Immunol 1999;163:6631-9.
15. Zeyda M, Szekeres AB, Saemann MD, Geyeregger R, Stockinger H, Zlabinger GJ, et al. Suppression of T cell signaling by polyun-saturated fatty acids: selectivity in inhibition of mitogen-activated protein kinase and nuclear factor activation. J Immunol 2003;170:6033-9. (Pubitemid 36682584)
16. Koike T, Yamagishi H, Hatanaka Y, Fukushima A, Chang JW, Xia Y, et al. A novel ERK-dependent signaling process that regulates interleukin-2 expression in a late phase of T cell activation. J Biol Chem 2003;278:15685-92. (Pubitemid 36799679)
17. Welsh GI, Miyamoto S, Price NT, Safer B, Proud CG. T-cell activation leads to rapid stimulation of translation initiation factor eIF2B and inactivation of glycogen synthase kinase-3. J Biol Chem 1996;271:11410-3. (Pubitemid 26155980)
18. Ohteki T, Parsons M, Zakarian A, Jones RG, Nguyen LT, Woodgett JR, et al. Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3. J Exp Med 2000;192:99-104. (Pubitemid 30470810)
19. Barcellini W, Rizzardi GP, Borghi MO, Nicoletti F, Fain C, Del Papa N, et al. In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: lack of relationship with clinical disease activity. Lupus 1996;5:139-45.
20. Linker-Israeli M, Bakke AC, Kitridou RC, Gendler S, Gillis S, Horwitz DA. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol 1983;130:2651-5.
21. Tsokos GC, Nambiar MP, Tenbrock K, Juang YT. Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE. Trends Immunol 2003;24:259-63.
22. Katsiari CG, Tsokos GC. Transcriptional repression of interleukin-2 in human systemic lupus erythematosus. Autoimmun Rev 2006;5:118-21.
23. Juang YT, Wang Y, Solomou EE, Li Y, Mawrin C, Tenbrock K, et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 2005;115:996-1005.
24. Luan HY, Tang SJ, Yang W, Tsai CY, Sun GH, Sun KH. Monoclonal anti-double-stranded DNA antibodies cross-react with phosphoglycerate kinase 1 and inhibit the expression and production of IL-2 in activated Jurkat T cell line. Clin Immunol 2006;120:326-34.
25. Iikuni N, La Cava A. Antibody-based therapies in systemic lupus erythematosus. Mini Rev Med Chem 2009;9:829-46.
26. Sun KH, Yu CL, Tang SJ, Sun GH. Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1β, IL-6, IL-8, IL-10 and TNF-α from normal human mononuclear cells involving in the lupus pathogenesis. Immunology 2000;99:352-60.
27. Sun KH, Tang SJ, Lin ML, Wang YS, Sun GH, Liu WT. Monoclonal antibodies against human ribosomal P proteins penetrate into living cells and cause apoptosis of Jurkat T cells in culture. Rheumatology (Oxford) 2001;40:750-6.
28. Sun KH, Tang SJ, Chen CY, Lee TP, Feng CK, Yu CL, et al. Monoclonal ribosomal P autoantibody inhibits the expression and release of IL-12, TNF-α and iNOS in activated RAW macrophage cell line. J Autoimmun 2005;24:135-43.
29. Song YC, Sun GH, Lee TP, Huang JC, Yu CL, Chen CH, et al. Arginines in the CDR of anti-dsDNA autoantibodies facilitate cell internalization via electrostatic interactions. Eur J Immunol 2008;38:3178-90.
30. Braunstein J, Autschbach F, Giese T, Lasitschka F, Heidtmann A, Sido B, et al. Up-regulation of the phosphoinositide 3-kinase pathway in human lamina propria T lymphocytes. Clin Exp Immunol 2008;151:496-504.
31. Sun KH, Tang SJ, Wang YS, Lin WJ, You RI. Autoantibodies to dsDNA cross-react with the arginine-glycine-rich domain of heterogeneous nuclear ribonucleoprotein A2 (hnRNP A2) and promote methylation of hnRNP A2. Rheumatology (Oxford) 2003;42:154-61.
32. Putterman C, Naparstek Y. The decade of autoimmunity. In Shoenfeld Y, editor. What does the wolf in lupus bite? Reflections on the nature of the target antigen in SLE. Amsterdam: Elsevier; 1999. p. 119-26.
33. Madaio MP, Yanase K. Cellular penetration and nuclear localization of anti-DNA antibodies: mechanisms, consequences, implications and applications. J Autoimmun 1998;11:535-8. (Pubitemid 28520212)
34. Putterman C. Cellular dysfunction induced by penetration of autoantibodies into living cells: cellular damage and dysfunction mediated by antibodies to dsDNA and ribosomal P proteins. Autoimmun Rev 2004;3:7-11.
35. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004;4:665-74.
36. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 2007;32:577-95. (Pubitemid 46481289)
37. Rodionova E, Conzelmann M, Maraskovsky E, Hess M, Kirsch M, Giese T, et al. GSK-3 mediates differentiation and activation of proinflammatory dendritic cells. Blood 2007;109:1584-92.
38. Hart DA, Done SJ, Benediktsson H, Lenz SP. Partial characterization of the enhanced survival of female NZB/W mice treated with lithium chloride. Int J Immunopharmacol 1994;16:825-33.
39. Lenz SP, Izui S, Benediktsson H, Hart DA. Lithium chloride enhances survival of NZB/W lupus mice: influence of melatonin and timing of treatment. Int J Immunopharmacol 1995;17:581-92.
40. Tsokos GC, Kammer GM. Molecular aberrations in human systemic lupus erythematosus. Mol Med Today 2000;6:418-24.
41. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001;345:340-50.
42. Stohl W, Elliott JE, Hamilton AS, Deapen DM, Mack TM, Horwitz DA. Impaired recovery and cytolytic function of CD56+ T and non-T cells in systemic lupus erythematosus following in vitro polyclonal T cell stimulation: studies in unselected patients and monozygotic disease-discordant twins. Arthritis Rheum 1996;39:1840-51.